Jon McGarity

Part of Quintiles Transnational Corp., Pharmaceutical Marketing Services, Inc. provides a range of information services to pharmaceutical and health care companies. The company is based in New York, NY. Pharmaceutical Marketing Services was acquired by Quintiles Transnational Corp. on March 30, 1999 for $189.59 million.

Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA.

Part of Novartis AG, Novartis, Inc. is a company based in San Francisco.

Restorative Biosciences, Inc. developed anti-fouling, anti-inflammatory coatings and therapeutics for ophthalmic applications. The company was founded by Chad E. Kennedy and was headquartered in Chandler, AZ.

GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada.

Syneos Health Consulting, Inc. provides consulting services to pharmaceutical and biotech industries. It is organized into practice areas, each specializing in a critical industry function: brand management, business development, clinical development, managed markets, medical affairs, sales, and trade and distribution. The company was founded by John J. Campbell in 1997 and is headquartered in Morrisville, NC.

Alare Capital Partners LLC provides investment advisory services. The firm provides services to the life sciences, technology, branded consumer and renewable energy sectors. The company was founded in 2005 and is headquartered in Phoenix, AZ.

InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ.